<?xml version="1.0" encoding="UTF-8"?>
<Label drug="buminate" track="TAC2017_ADR">
  <Text>
    <Section name="adverse reactions" id="S1">    ADVERSE REACTIONS

  Adverse Reactions from Clinical Trials

  There are no data available on adverse reactions from Baxter-sponsored clinical trials conducted with BUMINATE 25%.



   Post-Marketing Adverse Reactions  



 The following adverse reactions have been reported in the post-marketing experience.



   Immune System Disorders  : Anaphylactic shock, anaphylactic reaction, hypersensitivity/allergic reactions



   Nervous System Disorders  : Headache,dysgeusia



   Cardiac Disorders  : Myocardial infarction, atrial fibrillation, tachycardia



   Vascular Disorders  : Hypotension, flushing



   Respiratory, Thoracic, and Mediastinal Disorders  : Pulmonary edema, dyspnea



   Gastrointestinal Disorders  : Vomiting, nausea



   Skin and Subcutaneous Tissue Disorders  : Urticaria, rash, pruritus



   General Disorders and Administration Site Conditions  : Pyrexia, chills
</Section>
  </Text>
  <Mentions />
  <Relations />
  <Reactions />
</Label>
